With an industry-leading psychedelic drug R&D portfolio, MindMed has plenty of options to leverage its cash-on-hand to a higher share price.
Exploring the companies and themes that make up this emerging and exciting new sector
MindMed Announces the Completion of Phase 1 Study Measuring Dosing Effects of LSD
This dosing study on LSD will be utilized as MindMed prepares for its Phase 2b clinical trial of LSD for anxiety.
MindMed Closes Upsized Financing of CAD $28.75m With Strong Institutional Demand for Psychedelic Medicines
With MindMed's latest financing, total cash reserves now stand at CAD$50.1 million.
Wuhan General Group Updates on University of Pretoria Research Collaboration for Psilocybin Magic Mushroom Clinical Trials
M2Bio Sciences (Wuhan General Group) has finalized an agreement with the University of Pretoria (South Africa) to conduct a psilocybin-based clinical trial.
Hapbee to Commence Trading on the TSX Venture Exchange Under the Ticker Symbol "HAPB"
Fitness wearables company, Hapbee Technologies, is going to commence trading October 30th on the TSX Venture Exchange (symbol "HAPB").
Huge Cost-Savings From Psychedelic Drug Therapy
MAPS' recent economic study revealed huge cost savings from MDMA-assisted therapy to treat PTSD. But that could be just the beginning of the savings.
MPV announces CSE’s conditional approval of its transaction with Entheon Biomedical Corp.
Entheon Biomedical has received conditional approval from the CSE to commence public trading.
MAPS Study: MDMA-Assisted Psychotherapy Will Be More Cost-Effective than Other Treatments for PTSD
MDMA-assisted psychotherapy for PTSD is estimated to produce cost savings of $103,200 per patient, over a 30-year treatment horizon.
The 4 Best-Performing Psychedelic Stocks
As the new rally in psychedelic stocks progresses, these four companies are currently setting the pace.
How and Why Psychedelic Drugs Can Conquer The Mental Health Crisis
An enormous Crisis. Huge treatment markets. Massive disruption potential. Welcome to the psychedelic drug industry.
Field Trip Health Ltd. Continues Expansion With Psychedelic-Enhanced Therapy Center in Chicago
Field Trip Health opens a new clinic in Chicago, its 4th ketamine-assisted psychotherapy clinic.
Numinus First Canadian Public Company to Complete Legal Harvest of Psilocybe Mushrooms
Numinus announces its first psilocybin harvest and the appointment of a new Science Officer.